Petra Hoffknecht

976 total citations
27 papers, 625 citations indexed

About

Petra Hoffknecht is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Petra Hoffknecht has authored 27 papers receiving a total of 625 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Petra Hoffknecht's work include Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Petra Hoffknecht is often cited by papers focused on Lung Cancer Treatments and Mutations (20 papers), Lung Cancer Diagnosis and Treatment (11 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Petra Hoffknecht collaborates with scholars based in Germany, Switzerland and Italy. Petra Hoffknecht's co-authors include Amanda Tufman, Nicolas Dickgreber, Theo Pelzer, Rainer Wiewrodt, Angela Märten, Rudolf M. Huber, Monika Serke, Thomas Wehler, Martin Schütz and Michael Thomas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Petra Hoffknecht

25 papers receiving 616 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Petra Hoffknecht Germany	8	581	389	70	65	42	27	625
Hisao Uejima Japan	11	374 0.6×	371 1.0×	127 1.8×	44 0.7×	34 0.8×	22	549
M-J. Ahn South Korea	14	394 0.7×	517 1.3×	118 1.7×	54 0.8×	30 0.7×	68	622
HeeJong Baek South Korea	7	339 0.6×	252 0.6×	47 0.7×	75 1.2×	32 0.8×	11	399
Haruhito Kamei Japan	9	465 0.8×	389 1.0×	53 0.8×	32 0.5×	66 1.6×	37	573
Eduardo J. Pennella United States	11	377 0.6×	416 1.1×	82 1.2×	60 0.9×	49 1.2×	33	578
Catherine Dubos‐Arvis France	8	348 0.6×	310 0.8×	57 0.8×	104 1.6×	36 0.9×	11	476
Beung‐Chul Ahn South Korea	12	366 0.6×	497 1.3×	106 1.5×	30 0.5×	63 1.5×	38	621
Sufia Safina Russia	9	249 0.4×	272 0.7×	85 1.2×	40 0.6×	51 1.2×	28	397
Changli Wang China	13	450 0.8×	346 0.9×	89 1.3×	26 0.4×	37 0.9×	29	522
Carol A. Sherman United States	13	377 0.6×	317 0.8×	125 1.8×	24 0.4×	109 2.6×	28	554

Countries citing papers authored by Petra Hoffknecht

Since Specialization

Citations

This map shows the geographic impact of Petra Hoffknecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petra Hoffknecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petra Hoffknecht more than expected).

Fields of papers citing papers by Petra Hoffknecht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petra Hoffknecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petra Hoffknecht. The network helps show where Petra Hoffknecht may publish in the future.

Co-authorship network of co-authors of Petra Hoffknecht

This figure shows the co-authorship network connecting the top 25 collaborators of Petra Hoffknecht. A scholar is included among the top collaborators of Petra Hoffknecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petra Hoffknecht. Petra Hoffknecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Rajiv, Martin Reck, Christian Grohé, et al.. (2024). Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting.. Journal of Clinical Oncology. 42(16_suppl). 8085–8085. 1 indexed citations

Christopoulos, Petros, Franziska Herster, Petra Hoffknecht, et al.. (2024). Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report. Frontiers in Oncology. 14. 1347742–1347742.

Pirngruber, Judith, Eva‐Maria Willing, Markus Falk, et al.. (2023). The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology. 30(10). 8805–8814. 2 indexed citations

Evers, Georg, Daniel C. Christoph, Wolfgang M. Brueckl, et al.. (2023). 1300P Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab. Annals of Oncology. 34. S749–S749.

Shah, Rajiv, Laura V. Klotz, Daniel C. Christoph, et al.. (2023). Nivolumab with chemotherapy in pleural mesothelioma after surgery: The NICITA trial.. Journal of Clinical Oncology. 41(16_suppl). TPS8601–TPS8601. 1 indexed citations

Trummer, Arne, Nicolas Dickgreber, Heiko Golpon, et al.. (2022). NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy. Lung Cancer. 174. 141–145. 6 indexed citations

Trummer, Arne, Nicolas Dickgreber, Heiko Golpon, et al.. (2022). NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.. Journal of Clinical Oncology. 40(16_suppl). e21076–e21076. 2 indexed citations

Shumilov, Evgenii, Petra Hoffknecht, Raphael Koch, et al.. (2021). Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer Centers. Cancers. 13(12). 2917–2917. 2 indexed citations

Brueckl, Wolfgang M., Martin Reck, Achim Rittmeyer, et al.. (2021). Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Translational Lung Cancer Research. 10(7). 3093–3105. 27 indexed citations

10.

Faehling, Martin, Christian Schumann, Petra Hoffknecht, et al.. (2020). 1244P Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP). Annals of Oncology. 31. S806–S807. 1 indexed citations

11.

Faehling, Martin, Christian Schumann, Petros Christopoulos, et al.. (2020). Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer. 150. 114–122. 50 indexed citations

12.

Faehling, Martin, Christian Schumann, Petros Christopoulos, et al.. (2020). Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP. SHILAP Revista de lepidopterología. 34. 106556–106556. 3 indexed citations

13.

Griesinger, Frank, Wilfried Eberhardt, Petra Hoffknecht, et al.. (2020). 1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C. Annals of Oncology. 31. S872–S872. 1 indexed citations

14.

Hoffknecht, Petra, Amanda Tufman, Thomas Wehler, et al.. (2014). Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease. Journal of Thoracic Oncology. 10(1). 156–163. 217 indexed citations

15.

Thomas, Michael, Christian Rübe, Petra Hoffknecht, et al.. (2008). Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. The Lancet Oncology. 9(7). 636–648. 229 indexed citations

16.

Beyer, Florian, Petra Hoffknecht, Jan‐Martin Kuhnigk, et al.. (2006). CT-basierte softwaregestützte Vorhersage der postoperativen Lungenfunktion nach Lungenteilresektion. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren. 178(9). 872–879. 1 indexed citations

17.

Thomas, Michael, et al.. (2004). Non-small-cell lung cancer: multimodality approach in stage-III resectable disease. Lung Cancer. 45. S99–S105. 7 indexed citations

18.

Reinmuth, Niels, Rolf M. Mesters, Ralf Bieker, et al.. (2004). Signal transduction pathways as novel therapy targets in lung cancer. Lung Cancer. 45. S177–S186. 5 indexed citations

19.

Riesenbeck, D., M Semik, H.-N. Macha, et al.. (2004). Neoadjuvant chemotherapy followed by preoperative radiochemotherapy (hfRTCT) plus surgery or surgery plus postoperative radiotherapy in stage III non-small cell lung cancer: Results of a randomized phase III trial of the German lung cancer cooperative group. International Journal of Radiation Oncology*Biology*Physics. 60. S130–S130. 2 indexed citations

20.

Schumacher, Andrea, D. Riesenbeck, Achim Heinecke, et al.. (2003). Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life. Lung Cancer. 44(1). 89–97. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact